摘要
背景:由于目前使用的治疗剂的非特异性细胞毒活性,癌症化疗受到严重副作用的限制。为了尽量减少这些不必要的影响,已经采取了几种方法,依靠使用光来激活药物。由于光能够以非常高的时空分辨率传递,该技术是在其作用部位选择性激活细胞毒性药物并由此提高化疗的耐受性和安全性的有前景的策略。 目的:本综述总结了不同的光化学疗法的方法,并确定其挑战和机遇。 结果:根据各自的光疗指数和活化所需的波长对各篇论文进行总结和评估。首先描述了包括铂 - ,钌 - 和铑 - 配合物的光活化金属配合物的设计,合成和/或评价。接下来,报道了光学金属配合物和光敏有机化学治疗剂,具有广泛的细胞毒性机制。最后一部分包括用于癌症治疗的光敏药物的例子。 _一些设计,特别是金属络合物,由于其非常高的光治疗指数(> 1880)而突出,但是光响应性金属络合物和有机化学治疗剂的共同缺点是活化的不可逆性。然而,照片可切换的药物解决了这个挑战。尽管如此,紫外线对其激活的需求仍然限制了它们的应用。 结论:光敏化癌症化学疗法领域正在快速发展,已经包含了非常有前途的方法,其设计提供了高度的光治疗指数,并且还包括NIR或可见光活化的药物。
关键词: 光活化,癌症,化学疗法,光照,金属络合物,光药理学。
Current Medicinal Chemistry
Title:Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Volume: 24 Issue: 42
关键词: 光活化,癌症,化学疗法,光照,金属络合物,光药理学。
摘要: Background: Cancer chemotherapy is limited by severe side effects due to unspecific cytotoxic activity of currently used therapeutics. In order to minimize these unwanted effects, several approaches have been taken, relying on the use of light to activate drugs. As light can be delivered with a very high spatiotemporal resolution, this technique is a promising strategy to selectively activate cytotoxic drugs at their site of action and thus to improve the tolerability and safety of chemotherapy.
Objective: This review summarizes different approaches towards photoactivated chemotherapy and identifies its challenges and opportunities.
Results: The respective papers were summarized and evaluated in terms of their phototherapeutic indices and the wavelength needed for activation. First, the design, synthesis and/or evaluation of photoactivated metal complexes including platinum- , ruthenium-, and rhodium-complexes is described. Next, photocaged metal complexes and photoacaged organic chemotherapeutics are reported, with a wide range of cytotoxicity mechanisms. The final part includes, examples of photoswitchable drugs for cancer therapy.
Some designs, especially metal complexes, stand out due to their very high phototherapeutic index (> 1880) but the common drawback of light-responsive metal complexes and organic chemotherapeutics is the irreversibility of activation. Photoswitchable drugs, however, address this challenge. Nevertheless, the need of UV light for their activation still limits their application.
Conclusion: The field of photoactivated cancer chemotherapy is rapidly growing and already includes very promising approaches with designs providing high phototherapeutic indices and also NIR or visible light-activatable drugs.
Export Options
About this article
Cite this article as:
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy, Current Medicinal Chemistry 2017; 24 (42) . https://dx.doi.org/10.2174/0929867323666160906103223
DOI https://dx.doi.org/10.2174/0929867323666160906103223 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Theranostic Systems and Strategies for Monitoring Nanomedicine-Mediated Drug Targeting
Current Pharmaceutical Biotechnology Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets Towards Second Generation Hypericin Based Photosensitizers for Photodynamic Therapy
Current Organic Chemistry Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry Molecular Mechanisms of Anti-cancer Activities of β-elemene: Targeting Hallmarks of Cancer
Anti-Cancer Agents in Medicinal Chemistry Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Biochemical Markers of Renal Function
Current Medicinal Chemistry Inhibitors of Aldo-Keto Reductases AKR1C1-AKR1C4
Current Medicinal Chemistry Nanoparticles: Functionalization and Multifunctional Applications in Biomedical Sciences
Current Medicinal Chemistry Tumor Growth-Promoting Properties of Macrophage Migration Inhibitory Factor
Current Pharmaceutical Design Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry ES-MDA: Enhanced Similarity-based MiRNA-Disease Association
Current Protein & Peptide Science Targeting the HIF-1α/Cav-1 Pathway with a Chicory Extract/Daidzein Combination Plays a Potential Role in Retarding Hepatocellular Carcinoma
Current Cancer Drug Targets The Clustered DNA Lesions – Types, Pathways of Repair and Relevance to Human Health
Current Medicinal Chemistry Biopharmaceutics and Therapeutic Potential of Engineered Nanomaterials
Current Drug Metabolism Roles of Calcium and Tyrosine Kinases in the Pathogenesis of Type 2 Diabetes Mellitus
Current Enzyme Inhibition Selective Cyclooxygenase-2 Inhibitors and Non-small Cell Lung Cancer
Current Medicinal Chemistry RNA Splicing Manipulation: Strategies to Modify Gene Expression for a Variety of Therapeutic Outcomes
Current Gene Therapy Versatile Applications of microRNA in Anti-Cancer Drug Discovery: From Therapeutics to Biomarkers
Current Drug Discovery Technologies Relevance of Micrometastases and Targeting the Bone Marrow Niche with Zoledronic Acid in Breast Cancer
Current Cancer Therapy Reviews